Skip Navigation


NDT Advance Access first published online on June 13, 2008
This version published online on July 31, 2008
Nephrology Dialysis Transplantation, doi:10.1093/ndt/gfn322
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrowOA All Versions of this Article:
23/11/3711    most recent
gfn322v3
gfn322v2
gfn322v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Vychytil, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vychytil, A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2008].
The online version of this article has been published under an open access model. Users are entitled to use, reproduce, disseminate, or display the open access version of this article for non-commercial purposes provided that: the original authorship is properly and fully attributed; the Journal and Oxford University Press are attributed as the original place of publication with the correct citation details given; if an article is subsequently reproduced or disseminated not in its entirety but only in part or as a derivative work this must be clearly indicated. For commercial re-use, please contact journals.permissions@oxfordjournals.org


Icodextrin does not impact infectious and culture-negative peritonitis rates in peritoneal dialysis patients: a 2-year multicentre, comparative, prospective cohort study

Andreas Vychytil1, César Remón2, Catherine Michel3, Paul Williams4, Ana Rodríguez-Carmona5, Belén Marrón6, Ed Vonesh6, Synke van der Heyden6, Jose C. Divino Filho6 and on behalf of the Extraneal Peritonitis Study Group*

1 Division of Nephrology and Dialysis, Department of Medicine III, Medical University of Vienna, Austria 2 Division of Nephrology, Hospital Puerto Real, Cadiz, Spain 3 Division of Nephrology, Hôpital Bichat, Paris, France 4 Division of Nephrology, The Ipswich Hospital, Ipswich, UK 5 Division of Nephrology, Hospital Juan Canalejo, Coruna, Spain 6 Baxter Healthcare, Brussels, Belgium

Correspondence and offprint requests to: Andreas Vychytil, Division of Nephrology and Dialysis, Department of Medicine III, Medical University of Vienna, Waehringer Guertel 18-20, A-1090 Vienna, Austria. Tel: +43-1-40400-4495; Fax: +43-1-40400-4499; E-mail: andreas.vychytil{at}meduniwien.ac.at



  Abstract

Background. Icodextrin is a glucose polymer derived by hydrolysis of cornstarch. The different biocompatibility profile of icodextrin-containing peritoneal dialysis (PD) solutions may have a positive influence on peritoneal host defence. Furthermore, cases of sterile peritonitis potentially associated with icodextrin have been reported.

Methods. The primary objective of this multicentre, longitudinal, observational, non-interventional, prospective cohort study, which included 722 PD patients, was to evaluate the incidence of overall peritonitis in patients treated with icodextrin-containing PD solutions (ExtranealTM) used during one long-dwell exchange/day compared with those treated with non-icodextrin-containing PD solutions. The secondary objective was to determine if culture-negative peritonitis rates differed between patients treated with icodextrin from two independent manufacturers. All peritonitis episodes were assessed by a Steering Committee in a blind manner.

Results. There was no significant difference between icodextrin-treated and control patients in the adjusted overall, culture-positive or culture-negative peritonitis rates. When stratified by the icodextrin supplier, there was no significant difference in the adjusted rate of culture-negative peritonitis episodes between groups.

Conclusion. Subjects receiving icodextrin as part of their PD regimen experienced neither a higher rate of culture-negative peritonitis nor a lower rate of infectious peritonitis compared with non-icodextrin users. There was no significant influence of the icodextrin raw material supplier on peritonitis rates.

Keywords: biocompatibility; glucose degradation products; glucose polymer; peptidoglycan; sterile peritonitis

* Sites and members of the Extraneal Peritonitis Study Group are listed in the Appendix.

The original version of this paper was incorrect. An author name in the Appendix was incorrectly displayed.

Received for publication: 28.12.07
Accepted in revised form: 19. 5.08


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.